2015-06-01 17:42:51 UTC

Gastrointestinal and Hepatic Clinical Pharmacology

GI SAM

Duration

Self-Directed

About

GI SAM: Gastrointestinal and Hepatic Clinical Pharmacology is comprised of 30 board-style questions targeting the expanding complexities, improving agents and evolving base on the application of therapies. By identifying knowledge gaps and providing resources for self-directed learning, this module will serve as a useful tool in studying for the board exam as well as meeting the needs of a life-long learner.

  • Earn up to 10 AMA PRA Category 1 Credits™ and 10 points towards ABIM Maintenance of Certification (MOC).
  • References for further study.
  • Detailed images to further clarify important points.
  • Can be accessed anytime, anywhere.

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other health-care professionals who treat GI disorders.

Takeaways

Upon completing this educational activity, successful learners will be able to:

  • Comprehend medications needed in gastroenterology and hepatology.
  • Recognize various issues pertinent to patient safety.

About the Instructors

Module Editors  
Arthur J. DeCross, MD, AGAF*
University of Rochester
Amy S. Oxentenko, MD, AGAF, FACP, FACG
Mayo Clinic
Authors  
Brijen J. Shah, MD
Icahn School of Medicine at Mount Sinai
Michele Young, MD
Banner Good Samaritan Medical Center
Planning Committee  
Jane E. Onken, MD, MHS, AGAF Suzanne Rose, MD, MSEd, AGAF

*Also a member of the planning committee.

CME/MOC Information

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Successful completion of this CME activity enables the participant to earn up to 10 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points

Faculty Relationship and Financial Disclosures

Kiran Bambha, MD
Disclosed no relevant financial relationships.

Arthur J. DeCross, MD, AGAF
Disclosed no relevant financial relationships.

Lisa M. Gangarosa, MD, AGAF
Grant/Research Support: Ono Pharmaceuticals, Transtech Pharma

C. Prakash Gyawali, MD, MRCP, AGAF
Advisory Committee: AbbVie
Consulting: Covidien, AbbVie
Grant/Research Support: Given Imaging
Speakign and Teaching: Forrest/Ironwood, AbbVie

Jonathan C. Huang, MD
Disclosed no relevant financial relationships.

Amy S. Oxentenko, MD, AGAF, FACP, FACG
Disclosed no relevant financial relationships.

Brijen J. Shah, MD
Disclosed no relevant financial relationships.

Sonia S. Yoon, MD
Disclosed no relevant financial relationships.

Michele Young, MD
Disclosed no relevant financial relationships.

Planning Committee

Jane E. Onken, MD, MHS, AGAF
Member: BMS DMC
Major Stock Shareholder: Merck

Suzanne Rose, MD, MSEd, AGAF
Major Stock Shareholder: Abbott Labs, Baxter International, Johnson & Johnson, Novo Nordisk, Perrigo
Advisory Committees or Review Panels: AAMC

AGA Staff

Maura H. Davis
Disclosed no relevant financial relationships.

Natalie Foster
Disclosed no relevant financial relationships.

Lori N. Marks, PhD
Disclosed no relevant financial relationships.

More on CME Credit

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

Jan. 9, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.